Edgewise Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Edgewise Therapeutics

08/08/2024 15:16

* Edgewise Therapeutics Inc  EWTX.OQ  reported a quarterly
adjusted loss of 34 cents​​ per share for the quarter ended in
June, identical to the same quarter last year.  The mean
expectation of seven analysts for the quarter was for a loss
of 34 cents per share. Wall Street expected results to range
from -41 cents to -31 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Edgewise Therapeutics Inc's reported EPS for the quarter
was a
loss of 34 cents​.
    * The company reported a quarterly loss of $31.5 million.
    * Edgewise Therapeutics Inc shares had fallen by 11.8% this
quarter and gained 45.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 3.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Edgewise
Therapeutics Inc is $32.00 
This summary was machine generated from LSEG data August 8 at
02:16 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.34          -0.34          Met
 Mar. 31 2024      -0.39          -0.33          Beat
 Dec. 31 2023      -0.43          -0.47          Missed
 Sep. 30 2023      -0.40          -0.41          Missed